GlassScriptPhysician profile
Rex L Mahnensmith
NPI 1760466528
$1,917.92
in general payments reported to CMS, 2019-2025
20 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.17 · 2020: $767 · 2021: $105 · 2022: $190 · 2023: $191 · 2024: $482 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808 · Education: $6.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.29 |
| Education | $6.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $750.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $405.45 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $192.42 | 2023-2024 | |
| Abbvie INC. | $84.67 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.99 | 2022-2023 | Xifaxan |
| Genentech USA, INC. | $47.00 | 2021-2022 | |
| Novo Nordisk INC | $42.82 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $38.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.48 | 2022-2023 | Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $30.00 | 2025 | Tavneos |
| Calliditas Therapeutics US INC. | $29.81 | 2025 | Tarpeyo |
| Exact Sciences Corporation | $29.62 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $26.20 | 2024 | Korlym |
| Scilex Pharmaceuticals INC. | $23.72 | 2019 | |
| Indivior INC. | $21.53 | 2025 | Sublocade |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.52 | 2022 | |
| Mdd US Operations, LLC | $17.45 | 2019 | |
| Neurelis, INC. | $17.12 | 2020 | |
| Boston Scientific Corporation | $17.07 | 2024 | |
| Redhill Biopharma INC. | $16.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Mahnensmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.